NasdaqGM:CRVSBiotechs
Does Peer-Reviewed Phase 1 Soquelitinib Data Reshape The Bull Case For Corvus Pharmaceuticals (CRVS)?
Corvus Pharmaceuticals recently reported in Blood the final peer-reviewed Phase 1/1b data for its oral ITK inhibitor soquelitinib in advanced T cell lymphomas, showing durable responses, a median overall survival exceeding two years, and a favorable safety profile across multiple dose levels.
The publication strengthens the scientific case for soquelitinib’s selective ITK inhibition and Th1-skewing mechanism, underpinning Corvus’s ongoing registration Phase 3 PTCL trial and broader...